No profile data available.
Gain Therapeutics, Inc. (GANX) is a healthcare company in the brain and nerve treatment drugs industry, based in Bethesda, United States, with about 20 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$20.16 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $71.58 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.
Gain Therapeutics reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$71.58 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include ProMIS Neurosciences, Inc. (PMN), Cognition Therapeutics, Inc. (CGTX), MediciNova, Inc. (MNOV), Cingulate Inc. (CING).